Tirzepatide for Weight Loss: What Patients Should Know

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for chronic weight management in eligible adults (Zepbound™) and also used for type 2 diabetes (Mounjaro®).

How it works (high level): Tirzepatide activates two hormone pathways involved in appetite regulation and glucose metabolism. Like other GLP-1 class medications, it can reduce hunger and support weight loss when combined with lifestyle changes.

Candidate evaluation: A provider reviews BMI, metabolic health, medication history, and contraindications. Tirzepatide is not appropriate for everyone — pregnancy, certain thyroid conditions, and other factors may exclude use.

Side effects: Gastrointestinal effects — nausea, diarrhea, vomiting, constipation — are common especially during dose escalation. Injection-site reactions may occur. Report severe abdominal pain or persistent vomiting promptly.

Monitoring: Gradual dose titration and regular follow-up are standard. Labs may be checked based on your health profile. Progress is individual — clinical trial averages do not predict your personal results.

Compared to semaglutide: Both are GLP-1 class medications with overlapping mechanisms, though tirzepatide also targets GIP. Head-to-head studies exist, but the best choice for you depends on clinical evaluation — not online comparisons alone.

Medical supervision: Prescription GLP-1 therapy requires ongoing provider oversight. NeuMed medical weight loss consultations include candidacy assessment and follow-up planning.